JavaScript is unavailable or disabled; so you are probably going to miss out on a few things. Everything should still work, but with a little less pzazz!
The William Harvey Research Institute - Barts and The London

Professor Magdi Yaqoob

Joint Head of Department

Centre: Translational Medicine & Therapeutics

Email: m.m.yaqoob@qmul.ac.uk
Telephone: +44(0) 20 7882 2121

Profile

Magdi Yaqoob is Professor of Nephrology within Centre for Translational Medicine & Therapeutics at the William Harvey Research Institute (WHRI) and academic director of department of Renal Medicine and Transplantation at the Barts Health NHS Trust, UK. He graduated as one of the best graduates in Medicine (1982) from Dow Medical College, Karachi University, Pakistan. After general professional clinical training during which he obtained membership of the Royal College of Physician London (1985) he started specialist nephrology training in Liverpool, UK in 1987. He submitted his MD thesis on occupational factors in kidney disease in Liverpool University 1993. He obtained NIH fellowship to work as postdoctoral clinician/scientist under Prof Robert Schrier at Denver Colorado (194-1995).  He joined the Royal London Hospital as consultant in 1996 and was awarded personal chair in Nephrology by QMUL in 2011. He received several awards (best European young investigator of the year 1992 and trainee investigator of the year by association of physicians USA, 1994).  Magdi Yaqoob is an internationally recognised expert in nephrology and transplant medicine in area of cardiovascular diseases of uraemia, renal anaemia, and renal bone disease, progression of chronic kidney disease and mediators of acute kidney injury.

Research

•  NIHR Biomedical Research Centre at Barts  •  Inflammation: Translational Pharmacology & Therapeutic Innovation  •  Inflammation: Experimental Medicine & Pharmacology

Summary

Nephrology and Transplant Medicine Research Group

We have a long-standing research interest in the pathophysiology and novel therapeutic strategies (preclinical and clinical) of:

  1. Ischaemia-reperfusion of the heart in uraemia and kidney (acute kidney injury, chronic kidney disease, renal fibrosis)
  2. Genetic factors determining the long-term outcomes of renal transplants
  3. Insulin resistance in CKD
  4. Autophagy and premature ageing in uraemia
  5. Molecular mechanisms of EPO resistance.

Over the years, we have identified a number of new therapeutic targets poly (ADP-ribose) polymerase (PARP), Hypoxiainducible factor stabilizers, calpain/caspases, acidosis, anti-inflammatory suppression of cytokine signaling, pleiotropic effects of erythropoietin  their analogues, ischaemic preconditioning, sodium sensing in endothelial cells and galectins 1 & 3 in microcirculatory unit to  name but a few. More recently as part of the NIHR-funded Barts-BRU, we have focused on the development of highly translational repositioning strategies, the efficacy of which is currently evaluated in patients with chronic kidney disease and transplant waiting list patient.

Key Publications

For a full list of publist publications click here.
  • Byrne CJ, McCafferty K, Kieswich J, Harwood S, Andrikopoulos P, Raftery M, Thiemermann C, Yaqoob MM Ischemic conditioning protects the uremic heart in a rodent model of myocardial infarction.. Circulation. 2012;125(10):1256-65.
  • Tudhope SJ, Wang CC, Petrie JL, Potts L, Malcomson F, Kieswich J, Yaqoob MM, Arden C, Hampson LJ, Agius L. A novel mechanism for regulating hepatic glycogen synthesis involving serotonin and cyclin-dependent kinase-5. Diabetes;2012:61(1):49-60.
  • Caton PW, Kieswich J, Yaqoob MM, Holness MJ, Sugden MC. Nicotinamide mononucleotide protects against pro-inflammatory cytokine-mediated impairment of  mouse islet function. Diabetologia. 2011 54(12):3083-92.
  • Chapagain A, Dobbie H, Sheaff M, Yaqoob MM. Presentation, diagnosis, and treatment outcome of tuberculous-mediated tubulointerstitial nephritis. Kidney Int. 2011;79(6):671-7.
  • Hull S, Dreyer G, Yaqoob M. Collection of data on race and ethnic group by physician practices. N Engl J Med. 2010;363(1):96-7
  • Kumar S, Allen DA, Kieswich JE, Patel NS, Harwood S, Mazzon E, Cuzzocrea S, Raftery MJ, Thiemermann C, Yaqoob MM. Dexamethasone ameliorates renal ischemia-reperfusion injury. J Am Soc Nephrol. 2009;20(11):2412-25.
  • Varagunam M, Yaqoob MM, Döhler B, Opelz G. C3 polymorphisms and allograft outcome in renal transplantation. N Engl J Med.;360(9):874-80.
  • Kumar S, Fan SL, Raftery MJ, Yaqoob MM. Long term outcome of patients with autosomal dominant polycystic kidney diseases receiving peritoneal dialysis. Kidney Int. 2008;74(7):946-51
  • Rajakariar R, Lawrence T, Bystrom J, Hilliard M, Colville-Nash P, Bellingan G, Fitzgerald D, Yaqoob MM, Gilroy DW. Novel biphasic role for lymphocytes revealed during resolving inflammation. Blood. 2008;15;111(8):4184-92.
  • Rajakariar R, Hilliard M, Lawrence T, Trivedi S, Colville-Nash P, Bellingan G, Fitzgerald D, Yaqoob MM, Gilroy DW. Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyDelta12 14 PGJ2. Proc Natl Acad Sci USA. 2007;104(52):20979-84.

Sponsors

William Harvey Research Foundation

National Institute for Health Research

Kidney Research UK

Collaborators

Internal: Prof Chris Thiemermann (WHRI); Prof Mauro Perretti (WHRI); Prof Amrita Ahluwalia (WHRI); NIHR-funded Barts BRU; Prof Chris Thiemermann (WHRI); Prof Roger Corder (WHRI); Prof Tim Warner (WHRI).

External: Prof Anthony Cerami (University of Leiden, The Netherlands); Dr Massimo Collino (University of Turin, Italy); Prof Jonathan Sekl (Edinburgh University); Prof Derek Gilroy (UCH); Dr Andrew Wragg (Barthealth NHS UK).